On May 15, 2013, Seaside Therapeutics abruptly terminated their fragile X syndrome targeted, STX209/Arbaclofen extension due to a lack of funds. This termination has resulted in all children participating in the extension having to return their current supply of medication & begin the titration process. This drug is not currently available on the market & there are no alternative studies for many of the children to participate in. For those children this termination will result in unknown effects & potentially the loss of all benefits gained during the study.
We are seeking immediate funds to prevent the immediate termination giving the company & parents time to seek permanent funding.
Fragile X syndrome is the leading cause of inherited intellectual disability & genetic cause of autism.
This is historical material “frozen in time”. The website is no longer updated and links to external websites and some internal pages may not work.
